Clinical features of 14 patients with fluconazole non-susceptible bloodstream isolates of
Isolate No. | Age (yr)/sex | Diagnosis | Prior antifungal exposure | Immuno-suppression | CVC | Duration of fungemia (days) | Antifungal treatment | Patient outcome (days) |
---|---|---|---|---|---|---|---|---|
R1 | 30/F | Acute myeloid leukemia | Yes (AMB) | Yes | Yes | 5 | AMB, ANI | Death (6) |
R2 | 63/F | Pancreatic cancer | No | Yes | Yes | 1 | CAS | Death (52) |
R3 | 52/M | Diabetes mellitus | No | No | No | 10 | AMB | Improved |
R4 | 75/M | COPD | No | No | No | 3 | FLC | Death (19) |
R5 | 49/F | Breast cancer | No | No | Yes | 1 | None | Death (2) |
R6 | 52/M | T/NK-cell lymphoma | No | No | Yes | 5 | CAS | Death (7) |
R7 | 74/M | Diabetes mellitus | No | No | Yes | 1 | None | Death (1) |
R8 | 74/F | Chronic myeloid leukemia | Yes (FLC) | Yes | No | 2 | CAS | Death (4) |
R9 | 62/M | Rheumatoid arthritis | No | No | Yes | 4 | MICA | Improved |
R10 | 79/F | Traumatic subdural hemorrhage | No | No | Yes | 1 | FLC | Improved |
R11 | 80/M | Spinal abscess | No | No | Yes | 2 | CAS | Improved |
D1 | 79/M | Diabetes mellitus | Yes (AMB) | No | Yes | 8 | FLC | Death (15) |
D2 | 43/M | Down syndrome | No | Yes | Yes | 6 | AMB | Improved |
D3 | 67/F | Fulminant myocarditis, COPD | No | No | Yes | 1 | None | Death (3) |
*Time to death after the first positive culture.
Abbreviations: F, female; M, male; COPD, chronic obstructive pulmonary disease; AMB, amphotericin B; FLC, fluconazole; CVC, central venous catheter; ANI, anidulafungin; CAS, caspofungin; MICA, micafungin.
© Ann Lab Med